Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

被引：0

作者：

Schmid, P. ^{[1
]}

McArthur, H. L. ^{[2
]}

Cortes, J. ^{[3
,4
]}

Xu, B. ^{[5
]}

Cardoso, F. ^{[6
]}

Casalnuovo, M. L. ^{[7
]}

Demirci, U. ^{[8
]}

Freitas, R., Jr. ^{[9
]}

Ghosh, J. ^{[10
]}

Hegg, R. ^{[11
]}

Iwata, H. ^{[12
]}

Chuken, Y. A. Lopez ^{[13
]}

Nechaeva, M. ^{[14
]}

Robson, M. E. ^{[15
]}

Villalobos Valencia, R. ^{[16
]}

Lloyd, A. ^{[17
]}

D'Cruz, C. ^{[18
]}

Foxley, A. ^{[18
]}

Park, Y. H. ^{[19
]}

机构：

[1] Queen Mary Univ, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] UT Southwestern Med Ctr, Dallas, TX USA

[3] IBCC, Pangaea Grp, Barcelona, Spain

[4] IOB Madrid, Inst Oncol, Barcelona, Spain

[5] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[6] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[7] CENIT Ctr Med Neurociencias, Buenos Aires, DF, Argentina

[8] Mem Ankara Hosp, Ankara, Turkiye

[9] Hosp Araujo Jorge, Goiania, Go, Brazil

[10] Tata Med Ctr, Kolkata, India

[11] Sao Paulo State Govt Womens Hlth Reference Ctr, Sao Paulo, Brazil

[12] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[13] ICAN Oncol Ctr, Monterrey, Mexico

[14] Arkhangelsk Reg Clin Oncol Dispensary, Arkhangelsk, Russia

[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[16] Consultorio Ctr Torre Med Dalinde, Oncol Med, Mexico City, DF, Mexico

[17] AstraZeneca, Oncol R&D, Cambridge, England

[18] AstraZeneca, Oncol R&D, Waltham, MA USA

[19] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2257

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA19

引用

页码：1212 / 1213

页数：2

共 50 条

[1] Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)
Schmid, Peter
Cortes, Javier
Robson, Mark
Iwata, Hiroji
Hegg, Roberto
Verma, Sunil
Nechaeva, Marina
Xu, Binghe
Haddad, Vincent
Imedio, Esteban Rodrigo
Schiavon, Gaia
Foxley, Andrew
Park, Yeon Hee
CANCER RESEARCH, 2020, 80 (04)
[2] A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
Schmid, Peter
Cortes, Javier
Robson, Mark E.
Iwata, Hiroji
Hegg, Roberto
Nechaeva, Marina
Xu, Binghe
Verma, Sunil
Haddad, Vincent
Imedio, Esteban Rodrigo
Schiavon, Gaia
Foxley, Andrew
Park, Yeon Hee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Schmid, Peter
Abraham, Jacinta
Chan, Stephen
Wheatley, Duncan
Brunt, Adrian Murray
Nemsadze, Gia
Baird, Richard D.
Park, Yeon Hee
Hall, Peter S.
Perren, Timothy
Stein, Robert C.
Mangel, Laszlo
Ferrero, Jean-Marc
Phillips, Melissa
Conibear, John
Cortes, Javier
Foxley, Andrew
de Bruin, Elza C.
McEwen, Robert
Stetson, Daniel
Dougherty, Brian
Sarker, Shah-Jalal
Prendergast, Aaron
McLaughlin-Callan, Max
Burgess, Matthew
Lawrence, Cheryl
Cartwright, Hayley
Mousa, Kelly
Turner, Nicholas C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[4] IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
Emens, Leisha A.
Adams, Sylvia
Loi, Sherene
Schneeweiss, Andreas
Rugo, Hope S.
Winer, Eric P.
Barrios, Carlos H.
Dieras, Veronique
de la Haba-Rodriguez, Juan
Gianni, Luca
Chui, Stephen Y.
Schmid, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
Cortes Salgado, A.
Perez Garcia, J. M.
Cortez Castedo, S. P.
Gion Cortes, M.
Morales Murillo, S.
Blancas Lopez-Barajas, I.
Blanch, S.
Calvo Plaza, I.
Diaz Fernandez, N.
Marme, F.
Martinez Bueno, A.
Taberner Bonastre, M. T.
De laurentiis, M.
Ruiz Borrego, M.
Schmid, P.
Guarneri, V.
Gligorov, J.
Sampayo-Cordero, M.
Llombart Cussac, A.
Cortes, J.
ANNALS OF ONCOLOGY, 2022, 33 : S221 - S221
[6] tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
Yardley, Denise A.
Brufsky, Adam
Coleman, Robert E.
Conte, Pier Franco
Cortes, Javier
Glueck, Stefan
Nabholtz, Jean-Marc A.
O'Shaughnessy, Joyce
Li, Li
Barton, Debora
Beck, Robert M.
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial
Montagna, Emilia
Bagnardi, Vincenzo
Cancello, Giuseppe
Sangalli, Claudia
Pagan, Eleonora
Iorfida, Monica
Mazza, Manuelita
Mazzarol, Giovanni
Dellapasqua, Silvia
Munzone, Elisabetta
Goldhirsch, Aaron
Colleoni, Marco
BREAST CARE, 2018, 13 (03) : 177 - 181
[8] Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer
Tong, Zhongsheng
Li, Shufen
Shi, Yehui
Wang, Xu
Hao, Chunfang
He, Lihong
Dong, Guolei
Wang, Xiaorui
Jia, Yongsheng
Zhang, Li
CANCER RESEARCH, 2015, 75
[9] Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
Brufsky, Adam
Kim, Sung-Bae
Zvirbule, Zanete
Dirix, Luc Yves
Eniu, Alexandru E.
Carabantes, Francisco
Izarzugaza, Yann
Mebis, Jeroen
Sohn, Joohyuk
Wongchenko, Matthew
Chohan, Saibah
Amin, Reena
McNally, V. A.
Miles, David
Loi, Sherene
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
Emens, L.
Adams, S.
Loi, S.
Schmid, P.
Schneeweiss, A.
Rugo, H.
Chui, S.
Winer, E.
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →